SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

IMA203CD8

IMTX·https://immatics.com/
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Several years away, if successful. The drug is still in Phase 1 dose expansion with no registrational trial started.
Why 4/10
IMA203CD8 is in an ongoing Phase 1 trial with no hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The next catalyst is continued dose-expansion data updates at medical conferences, which are non-binary events.
Actionable Insight NEUTRAL

Watch for further Phase 1 dose-expansion data updates from Immatics' PRAME franchise at upcoming medical conferences. The more immediate binary catalyst for Immatics is the SUPRAME Phase 3 topline readout for anzu-cel (IMA203) in H1 2027, which is a separate, more advanced asset. IMA203CD8 remains an early-stage pipeline program.

Price Chart

Loading chart...

Executive Summary

IMA203CD8 is Immatics' second-generation PRAME-targeting TCR T-cell therapy in Phase 1 testing for advanced solid tumors. Updated data from October 2026 (ESMO) showed a 51% objective response rate across 98 heavily pretreated patients with various PRAME-positive cancers, with particular activity in gynecologic tumors. The drug is still early-stage with no registrational trial or regulatory filing on the horizon. Immatics' more advanced asset, anzu-cel (IMA203), is in a Phase 3 trial (SUPRAME) with topline data expected H1 2027. IMA203CD8 is one of three PRAME franchise programs at Immatics, alongside anzu-cel and the bispecific IMA402.

How It Works

IMA203CD8 is a second-generation T-cell receptor (TCR) T-cell therapy. Doctors take a patient's own immune T-cells, genetically engineer them to recognize a protein called PRAME that is found on many cancer cells, and infuse them back into the patient as a one-time treatment. The "CD8" designation means it is designed to activate CD8+ killer T-cells, which directly attack tumors. PRAME is a target expressed in more than 50 cancer types.

Trial Status

IMA203CD8 is in an ongoing Phase 1 dose-escalation and dose-expansion trial in heavily pretreated patients with PRAME-positive advanced solid tumors. Phase 1a dose escalation is complete. The company is enrolling patients with uterine cancer at clinically relevant doses to expand the dataset. Updated data as of an August 7, 2026 cutoff showed a 51% objective response rate across 98 patients in multiple solid tumor types.

The Two-Sided Case

▲ Bull Case5
51% objective response rate in 98 heavily pretreated patients across multiple solid tumor types is encouraging for an early Phase 1 cell therapy.
Second-generation design with enhanced pharmacology may offer improved potency over first-generation TCR-T approaches.
PRAME is a validated target expressed in over 50 cancer types, giving broad potential addressable market.
Immatics has strong institutional backing: RTW Investments ($131M), Baker Bros. ($96M), and Jefferies ($66M) held large positions as of Q2 2026.
Analyst consensus is Strong Buy (8 Buy, 1 Hold) with a mean price target of $16.40, implying ~144% upside from the $6.71 close.
▼ Bear Case5
Still very early-stage (Phase 1); cell therapies for solid tumors have historically struggled with efficacy and durability compared to blood cancers.
No registrational trial design or regulatory filing timeline has been announced, meaning commercialization is likely years away.
Immatics is burning cash (Q3 2026 net loss of ~$87.5M) and will need additional financing to fund its pipeline.
Toronto Dominion Bank fully exited its IMTX position in Q2 2026 (previously $73M), and several other funds trimmed significantly.
Competition in PRAME-targeting and TCR-T space is intensifying, including from Immatics' own anzu-cel (Phase 3) and IMA402 bispecific programs.

Upcoming Catalysts

  • Continued Phase 1 dose-expansion data updates at future medical conferences.
  • Potential initiation of a registrational cohort or Phase 2 trial design for IMA203CD8.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

https://immatics.com/ PRESS-RELEASE IMTX ·Originating report

Sources · 8

Hover a chip for the title
1 msn.com2 markets.businessinsider.com3 nasdaq.com4 msn.com5 markets.businessinsider.com6 nasdaq.com7 msn.com8 markets.financialcontent.com